Literature DB >> 21778573

Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.

Kathryn J Chavez1, Sireesha V Garimella, Stanley Lipkowitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21778573      PMCID： PMC3532890          DOI： 10.3233/BD-2010-0307

Source DB:  PubMed          Journal:  Breast Dis        ISSN： 0888-6008


× No keyword cloud information.
  106 in total

1.  bcl-2 suppresses expression of p21WAF1/CIP1 in breast epithelial cells.

Authors:  S Upadhyay; G Li; H Liu; Y Q Chen; F H Sarkar; H R Kim
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

2.  Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients.

Authors:  J H Wong; B Aguero; R K Gupta; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.

Authors:  J Bartek; R Iggo; J Gannon; D P Lane
Journal:  Oncogene       Date:  1990-06       Impact factor: 9.867

4.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

5.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

Authors:  R M Hudziak; G D Lewis; M Winget; B M Fendly; H M Shepard; A Ullrich
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

6.  Amplification of the epidermal growth factor receptor gene in the BT20 breast carcinoma cell line.

Authors:  J Lebeau; G Goubin
Journal:  Int J Cancer       Date:  1987-08-15       Impact factor: 7.396

7.  Transforming activity of the human mammary line HBL100 DNA is associated with SV40 large T antigen genetic information integrated in its genome.

Authors:  L Vanhamme; C Szpirer
Journal:  Carcinogenesis       Date:  1988-04       Impact factor: 4.944

8.  Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genes.

Authors:  M Theile; S Hartmann; H Scherthan; W Arnold; W Deppert; R Frege; F Glaab; W Haensch; S Scherneck
Journal:  Oncogene       Date:  1995-02-02       Impact factor: 9.867

9.  Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.

Authors:  R J Pietras; B M Fendly; V R Chazin; M D Pegram; S B Howell; D J Slamon
Journal:  Oncogene       Date:  1994-07       Impact factor: 9.867

10.  Epithelial HBL-100 cell line derived from milk of an apparently healthy woman harbours SV40 genetic information.

Authors:  C Caron de Fromentel; P C Nardeux; T Soussi; C Lavialle; S Estrade; G Carloni; K Chandrasekaran; R Cassingena
Journal:  Exp Cell Res       Date:  1985-09       Impact factor: 3.905
View more
  238 in total

1.  The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.

Authors:  Jennifer L Dine; Ciara C O'Sullivan; Donna Voeller; Yoshimi E Greer; Kathryn J Chavez; Catherine M Conway; Sarah Sinclair; Brandon Stone; Laleh Amiri-Kordestani; Anand S Merchant; Stephen M Hewitt; Seth M Steinberg; Sandra M Swain; Stanley Lipkowitz
Journal:  Breast Cancer Res Treat       Date:  2016-01-12       Impact factor: 4.872

2.  Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness.

Authors:  Eric Hesse; Saskia Schröder; Diana Brandt; Jenny Pamperin; Hiroaki Saito; Hanna Taipaleenmäki
Journal:  JCI Insight       Date:  2019-04-09

3.  Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.

Authors:  Sanghoon Lee; Yiheng Hu; Suet Kee Loo; Ying Tan; Rohit Bhargava; Michael T Lewis; Xiao-Song Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-22       Impact factor: 11.205

4.  Rutin as A Novel c-Met Inhibitory Lead for The Control of Triple Negative Breast Malignancies.

Authors:  Heba E Elsayed; Hassan Y Ebrahim; Mohamed M Mohyeldin; Abu Bakar Siddique; Amel M Kamal; Eman G Haggag; Khalid A El Sayed
Journal:  Nutr Cancer       Date:  2017-10-30       Impact factor: 2.900

5.  Rab34 regulates adhesion, migration, and invasion of breast cancer cells.

Authors:  Lixiang Sun; Xiaohui Xu; Yongjun Chen; Yuxia Zhou; Ran Tan; Hantian Qiu; Liting Jin; Wenyi Zhang; Rong Fan; Wanjin Hong; Tuanlao Wang
Journal:  Oncogene       Date:  2018-04-06       Impact factor: 9.867

6.  Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.

Authors:  Dong-Joon Min; Siping He; Jeffrey E Green
Journal:  Anticancer Res       Date:  2016-06       Impact factor: 2.480

Review 7.  Role of the androgen receptor in triple-negative breast cancer.

Authors:  Murtuza Rampurwala; Kari B Wisinski; Ruth O'Regan
Journal:  Clin Adv Hematol Oncol       Date:  2016-03

8.  Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells.

Authors:  Oana Tudoran; Olga Soritau; Loredana Balacescu; Simona Visan; Otilia Barbos; Roxana Cojocneanu-Petric; Ovidiu Balacescu; Ioana Berindan-Neagoe
Journal:  Mol Cell Biochem       Date:  2015-07-18       Impact factor: 3.396

9.  A Three-Dimensional In Vitro Coculture Model to Quantify Breast Epithelial Cell Adhesion to Endothelial Cells.

Authors:  Swathi Swaminathan; Aaron N Cranston; Alisa Morss Clyne
Journal:  Tissue Eng Part C Methods       Date:  2019-09-26       Impact factor: 3.056

10.  Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.

Authors:  Rebecca L Vartuli; Hengbo Zhou; Lingdi Zhang; Rani K Powers; Jared Klarquist; Pratyaydipta Rudra; Melanie Y Vincent; Debashis Ghosh; James C Costello; Ross M Kedl; Jill E Slansky; Rui Zhao; Heide L Ford
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.